Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorapaxar for lower extremity vein graft maturation
NCT02975583Phase 4
Key facts
- Status
- Withdrawn
- Start
- Oct 2017
- Primary completion
- Jan 2018
- Sponsor
- Vanderbilt University
- Modality
- Small Molecules
- Drugs
- vorapaxar
- Conditions
- peripheral artery disease (PAD)
01
Overview
Phase 4, randomised, double-blind trial of vorapaxar in peripheral artery disease (PAD), sponsored by Vanderbilt University. Primary endpoint: Bypass Graft Flow Mediated Vasodilation at 180 days. Planned start Oct 2017; status: withdrawn.
02
Design
- Study design
- RandomizedDouble-blind
03
Who it enrols
Patients aged 35+ with Rutherford class 3-5 PAD planned for lower extremity bypass grafting, excluding those with severe renal dysfunction (eGFR <= 30) or prior infrainguinal revascularization.
04
Endpoints
Primary
Bypass Graft Flow Mediated Vasodilation
Beyond the preview
Go deeper on NCT02975583.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02975583.